BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2009

View Archived Issues

FDA grants priority review to Shire's NDA for velaglucerase alfa in Gaucher disease

Read More

Oroxcell discovers novel sodium channel inhibitors for the treatment of pain

Read More

Graceway acquires worldwide rights to GS-9191 from Gilead Sciences

Read More

Phase III results show activity of omiganan 1% gel against catheter-related infections

Read More

FDA grants clearance to Arkray's Glucocard Vital blood glucose monitoring system

Read More

Bupropion improves hypoactive sexual desire disorder in women

Read More

Guided Therapeutics reports trial results of LightTouch in cervical cancer detection

Read More

Interim results of phase III study with CIMAvax EGF vaccine in NSCLC reported

Read More

Tesofensine effects on weight lead to phase III investigation

Read More

Subcutaneous abatacept may be delivered without methotrexate to treat RA

Read More

Pilot clinical data suggest beneficial effects of transdermal nicotine in mild cognitive impairment

Read More

Azathioprine superior to mycophenolate mofetil as maintenance therapy for ANCA-AAV

Read More

Gruenenthal presents ORL1 and mu-opioid receptor ligands as analgesics

Read More

IRM claims GDIR ligands for the treatment of diabetes and obesity

Read More

China Medical Technologies receives approval for its leukemia gene detection probe

Read More

Compugen discovers genetic biomarker for predisposition to type 2 diabetes

Read More

Evotec and Boehringer Ingelheim extend research collaboration

Read More

Bristol-Myers Squibb discloses IGF-1R inhibitors for the treatment of cancer

Read More

Daval's Aimspro is designated orphan drug for amyotrophic lateral sclerosis

Read More

Xoma to develop XOMA-052 antibody for cardiovascular diseases

Read More

Genmab starts phase III trial of ofatumumab in diffuse large B-cell lymphoma

Read More

Health Canada accepts for review EpiCept's NDS for Ceplene in AML

Read More

FDA extends review date of GSK's and XenoPort's NDA for gabapentin enacarbil

Read More

Concert Pharmaceuticals begins phase Ib clinical trial of HIV therapeutic CTP-518

Read More

D-Pharm enters into collaboration with Wanbang Biopharmaceuticals for DP-b99

Read More

GlaxoSmithKline reports third quarter 2009 results

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing